Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
blood cancer
Pharma
Novartis refreshes myelofibrosis bid as Geron flops in ph. 3
Geron's Rytelo failed to move the needle in post-JAK myelofibrosis, as Novartis is gearing up for a delayed FDA approval bid for its pelabresib.
Angus Liu
Oct 29, 2026 8:15am
Lilly’s BTK drug Jaypirca enters first-line CLL
Oct 2, 2026 4:15pm
Roche reports positive confirmatory trial readout for Lunsumio
Sep 17, 2026 11:25am
FDA approves label expansion for PharmaEssentia's Besremi
Aug 31, 2026 8:25am
Takeda wins FDA nod for first-in-class blood cancer drug Mimrylo
Aug 28, 2026 10:04pm
Roche tops cancer reputation rankings as AstraZeneca climbs back
Jul 2, 2026 6:00am
